Equillium Raises $35M, Names New CDO, EQ504 Phase 1 Trial Starts Mid-2026
Equillium secured $35 million in March financing from RA Capital to advance EQ504, which is set to begin a Phase 1 proof-of-mechanism trial in mid-2026 with data expected six months later. Appointment of Snehal Naik as Chief Development Officer strengthens clinical leadership, and cash reserves are projected to fund operations into 2029.
1. First Quarter 2026 Financial Results
Equillium reported a net loss for the quarter ended March 31, 2026, driven by ongoing research and development and general administrative expenses. Cash and cash equivalents remain sufficient to fund planned operations into 2029.
2. EQ504 Preclinical and Clinical Progress
The company plans to initiate a Phase 1 proof-of-mechanism study of EQ504 in mid-2026, with topline data anticipated six months later. Preclinical data presented in April demonstrated that EQ504 induces IL-10 and IL-22, promotes anti-inflammatory macrophage polarization and enhances epithelial repair.
3. $35 Million Private Placement Financing
In March, Equillium completed a $35 million private placement with RA Capital Management to support advancement of EQ504 through key clinical milestones and broader pipeline development. The financing underpins the company’s strategy to transition its lead asset into clinical testing.
4. Leadership Appointment
Equillium appointed Snehal Naik, Ph.D., as Chief Development Officer to lead clinical development and medical strategy across its immunology pipeline. Dr. Naik brings over 15 years of experience in gastrointestinal and inflammatory disease programs, including late-stage readiness and product lifecycle management.